PROCEPT BioRobotics, which makes a surgical robotic system for minimally-invasive urologic surgery, announced terms for its IPO on Wednesday.
The Redwood City, CA-based company plans to raise $127 million by offering 5.5 million shares at a price range of $22 to $24. At the midpoint of the proposed range, PROCEPT BioRobotics would command a fully diluted market value of $1.1 billion.
PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System, a surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia. Its proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy. As of June 30, 2021, PROCEPT BioRobotics had an installed base of 124 AquaBeam Robotic Systems, and Aquablation therapy had been utilized in the treatment of more than 5,500 patients.
PROCEPT BioRobotics was founded in 2009 and booked $21 million in revenue for the 12 months ended June 30, 2021. It plans to list on the Nasdaq under the symbol PRCT. BofA Securities, Goldman Sachs, Cowen, Guggenheim Securities, and SVB Leerink are the joint bookrunners on the deal. It is expected to price during the week of September 13, 2021.
